Comparison · NCT00397189-sae
Circadin vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Circadin vs Placebo: serious adverse events. Trial comparisons, record NCT00397189-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00397189-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00254 | 0.000448 | 0.0142 | wilson | |
| Risk in group 2 | 0.00759 | 0.00259 | 0.0221 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00506 | -0.0197 | 0.00767 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.334 | 0.0349 | 3.2 | log | |
| Odds ratio, group 1 over group 2 | 0.332 | 0.0344 | 3.21 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Circadin than on Placebo | 198 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Circadin | Prolonged release melatonin 2 mg. Tablets should be taken 1-2 hours before going to bed. | 1 | 394 | EG000 |
| Group 2 | Placebo | Identical tablets to Circadin. Tablets should be taken 1-2 hours before going to bed. | 3 | 395 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 37 weeks (2 weeks baseline, 3 weeks double-blind, 26 weeks double-blind extension period and 2 weeks run-out,AEs were to be reported for up to 30 days after stopping study medication )
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients
- NCT number
- NCT00397189
- Phases
- PHASE3
- Conditions
- Primary Insomnia
- Interventions
- Circadin, placebo circadin
- Lead sponsor
- Neurim Pharmaceuticals Ltd.
- Results first posted
- 2011-03-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00397189?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00397189-sae